Characterization of SARS-CoV main protease and identification of biologically active small molecule inhibitors using a continuous fluorescence-based assay  by Kao, Richard Y. et al.
FEBS 28858 FEBS Letters 576 (2004) 325–330Characterization of SARS-CoV main protease and identiﬁcation
of biologically active small molecule inhibitors using a
continuous ﬂuorescence-based assayRichard Y. Kao*, Amanda P.C. To, Louisa W.Y. Ng, Wayne H.W. Tsui, Terri S.W. Lee,
Hoi-Wah Tsoi, Kwok-Yung Yuen
Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong, China
Received 22 June 2004; revised 9 September 2004; accepted 13 September 2004
Available online 25 September 2004
Edited by Judit OvadiAbstract Severe acute respiratory syndrome associated coro-
navirus main protease (SARS-CoV Mpro) has been proposed as a
prime target for anti-SARS drug development. We have cloned
and overexpressed the SARS-CoV Mpro in Escherichia coli, and
puriﬁed the recombinant Mpro to homogeneity. The kinetic
parameters of the recombinant SARS-CoV Mpro were charac-
terized by high performance liquid chromatography-based assay
and continuous ﬂuorescence-based assay. Two novel small
molecule inhibitors of the SARS-CoV Mpro were identiﬁed by
high-throughput screening using an internally quenched ﬂuoro-
genic substrate. The identiﬁed inhibitors have Ki values at low
lM range with comparable anti-SARS-CoV activity in cell-
based assays.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Severe acute respiratory syndrome (SARS) swept through
the world last year, infecting more than 8000 people across 29
countries and causing more than 900 fatalities [1]. The etio-
logical agent of SARS was identiﬁed rapidly as a novel coro-
navirus of possible zoonotic origin [2–4]. Inadequate
knowledge of the novel coronavirus SARS-CoV and the ab-
sence of eﬃcacious therapeutics, however, were the main rea-
sons for the failure to improve the outcome of the patients and
to manage the outbreak of SARS eﬀectively.* Corresponding author. Fax: +852-28167415.
E-mail address: rytkao@hkucc.hku.hk (R.Y. Kao).
Abbreviations: SARS-CoV, severe acute respiratory syndrome associ-
ated coronavirus; Mpro, main protease; HPLC, high performance
liquid chromatography; HTS, high throughput screening; RT-PCR,
reverse transcription polymerase chain reaction; PCR, polymerase
chain reaction; IPTG, isopropyl b-D-thiogalactoside; DABCYL, 4-(4-
dimethylaminophenylazol)benzoyl; EDANS, 5-(2-aminoethylamino)-
1-naphthalenesulphonic acid; CPE, cytopathic eﬀect; PRA, plaque
reduction assay; EMEM, Eagle’s minimal essential medium; FBS, fetal
bovine serum; PFU, plaque forming unit; MTT, 3-[4,5-dimethylth-
iazol-2-yl]-2,5-diphenyltetrazolium bromide; CMV, cytomegalovirus
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doi:10.1016/j.febslet.2004.09.026Similar to other coronaviruses, SARS-CoV is an enveloped,
positive-strand RNA virus with a large single-strand RNA
genome comprised of 29 700 nucleotides [5,6]. Among vari-
ous open reading frames identiﬁed, the replicase gene encodes
two overlapping polyproteins, pp1a and pp1ab, and comprises
approximately two-thirds of the genome. Since the viral
polyproteins are largely processed by the main protease (Mpro),
and based on the successful development of eﬃcacious antiv-
iral agents targeting 3C-like proteases in other viruses, this
‘‘essential’’ protease is considered as a prime target for anti-
SARS drug development [7,8]. In addition, the recently
available crystal structure of the SARS-CoV Mpro has made
possible the employment of structure-based drug design to
develop Mpro-speciﬁc inhibitors [9].
To date, a number of potential inhibitors of SARS-CoV
have been proposed using molecular modelling and virtual
screening techniques [10–14]. However, the inhibitory activities
of most of the proposed inhibitors have not yet been examined
in in vitro assays employing puriﬁed SARS-CoV Mpro and
synthetic substrates because of the tedious procedures involved
in conventional high performance liquid chromatography
(HPLC)-based cleavage assays. In addition, HPLC-based
cleavage assays are impractical for high-throughput screening
(HTS) of thousands of compounds from chemical libraries. A
continuous ﬂuorescence-based assay system will therefore be
of great interest to the ﬁeld for the rapid screening and eval-
uation of the potencies of potential inhibitors of SARS-CoV
Mpro.
We have acquired a chemical library (ChemBridge Corpo-
ration) of 50 240 structurally diverse small molecule com-
pounds that vary in functional groups and charges. A diverse
chemical library was purposely chosen for anti-SARS drug
screening, since we set out to isolate biologically active small
molecules perturbing various viral components of the SARS-
CoV in a cellular model of infection. A total of 104 compounds
protected permissive Vero cells (African green monkey kidney
cells) from SARS-CoV infection. Identiﬁcation of inhibitors of
SARS-CoV Mpro from this pool of compounds using con-
ventional HPLC-based assays is labor-intensive and time
consuming. Here, we report the enzymatic characterization of
a recombinant SARS-CoV Mpro with authentic SARS-CoV
Mpro amino acid sequence and the employment of a continu-
ous ﬂuorescence-based assay to identify novel small molecule
inhibitors of SARS-CoV Mpro. The eﬃcacies of the 2 selectedblished by Elsevier B.V. All rights reserved.
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says. Our study has deﬁned the kinetic parameters of SARS-
CoV Mpro in HPLC-based and continuous ﬂuorescence-based
assays and validated the usefulness of the ﬂuorescence-based
assay in HTS. Our results also provide biologically active novel
non-peptide lead compounds for rational drug design of
SARS-CoV Mpro inhibitors.2. Materials and methods
2.1. Cloning of SARS-CoV Mpro and construction of plasmid pET
SVMP
SARS-CoV (strain HKU39849) RNA was extracted from cell ly-
sates of virus-infected Vero cells (African green monkey kidney cell
line) by TRIZOL (Invitrogen) according to the manufacturer’s in-
structions. Reverse transcription was performed using Thermoscript
RT-PCR system purchased from Invitrogen. The full-length cDNA
was subsequently ampliﬁed by PCR using forward primer SVMPF
(50-CGCGGATCCGATCGAAGGTCGTAGTGGTTTTAGGAAA-
ATG-30) and reverse primer SVMPR (50-CGGAATTCTTATTG-
GAA-GGTAACACCAGA-30). PCR product was separated by
agarose gel electrophoresis, puriﬁed using QIAquick gel extraction
kit (Qiagen), digested with BamHI and EcoRI restriction endonuc-
leases, ligated to BamHI–EcoRI-digested pET28b DNA (Novagen),
and transformed into E. coli DH5a cells by electroporation to gen-
erate pET SVMP. The nucleotide sequence of the SARS-CoV Mpro
gene in plasmid pET SVMP was sequenced to conﬁrm that no un-
desired mutation has been introduced. The construct was designed in
a way that a factor Xa cleavage site was engineered in the N-ter-
minus of the SARS-CoV Mpro (His-Tag. . .IEGR #SGFRKM. . .; the
factor Xa cleavage site is indicated with a # and the released N-
terminal part of the SARS-CoV Mpro is bolded). Cleavage with
factor Xa releases the His-tag and yields recombinant SARS-CoV
Mpro with authentic SARS-CoV Mpro amino acid sequence. The
identity of the puriﬁed SARS-CoV Mpro was determined by mass
spectrometry (Genome Research Centre, the University of Hong
Kong).
2.2. Protein expression and puriﬁcation
Escherichia coli BL21 Gold (DE3) cells (Novagen) transformed with
plasmid pET SVMP were grown to A600 ¼ 0:5 at 37 C with shaking in
Luria-Bertani broth containing 50 lg/ml of kanamycin. The culture
was induced with 0.5 mM of isopropyl b-D-thiogalactoside (IPTG) and
grown at 30 C with shaking for 4 h. Cells were harvested by centri-
fugation at 5000 g at 4 C for 20 min and disrupted by sonication in
buﬀer A containing 20 mM Tris–HCl, pH 7.3, and 150 mM NaCl.
Lysed cells were centrifuged at 12 000 g for 30 min and the super-
natant was decanted for further manipulation. The fusion SARS-CoV
Mpro was puriﬁed by aﬃnity puriﬁcation using HiTrapTM Chelating
column (Amersham Biosciences), cleaved with factor Xa to release the
N-terminal His-tag, and the recombinant SARS-CoVMpro with amino
acid sequence identical to authentic SARS-CoV Mpro was further
puriﬁed by anion-exchange chromatography using Q Sepharose Fast
Flow column (Amersham Biosciences) followed by size exclusion
chromatography using HiLoadTM 16/60 Superdex 75 column (Amer-
sham Biosciences).
2.3. HPLC-based cleavage assay
A synthetic peptide with the sequence H2N-TSAVLQ # SGFRKW-
COOH (SP1) mimicking the autolytic cleavage site (the cleavage site is
indicated with a #) of the N-terminal part of Mpro was synthesized by
SynPep Corporation. Cleavage assays were ﬁrst carried out at 25 C in
buﬀer A with 200 nM of puriﬁed SARS-CoV Mpro and 500 lM of the
synthetic substrate. The cleavage products were resolved by HPLC
using a SOURCETM 5RPC column (2.1 mm 150 mm) (Amersham
Biosciences) with a 20 min linear gradient of 10–30% acetonitrile in
0.1% triﬂuoroacetic acid. The absorbance was determined at 215 or
280 nm and peak areas were integrated to quantify the cleavage
products. The kinetic parameters were determined by Lineweaver–
Burk plot using 0.6–2.4 mM of synthetic substrate SP1 with 200 nM of
Mpro in identical conditions. The identities of the cleavage productswere conﬁrmed by mass spectrometry (Genome Research Centre, the
University of Hong Kong).
2.4. Fluorescence-based kinetic analysis
A synthetic ﬂuorogenic peptide DABCYL-SAVLQ # SGFRK-
EDANS (SP2) mimicking the autolytic cleavage site (the cleavage site
by SARS-CoV Mpro is indicated with a #) was synthesized by SynPep
Corporation. Cleavage of the ﬂuorogenic peptide was monitored
continuously by a F-4500 ﬂuorescence spectrophotometer (Hitachi)
using an excitation wavelength of 355 nm (10 nm slit) and emission
wavelength of 495 nm (10 nm slit). Standard assay conditions were
buﬀer A at 25 C. Initial ﬂuorescence was measured for substrate
concentrations from 2.5 to 50 lM. To establish the linearity between
enzyme concentration and rate of cleavage, the initial rate of change of
ﬂuorescence was measured at several SARS-CoV Mpro concentrations
(100–800 nM) using 5 lM ﬂuorogenic peptide as substrate. Assuming
that the substrate concentration used was much lower than the Km of
SARS-CoV Mpro, we determined the kinetic parameters and ﬂuores-
cent properties of the substrate using the following equations
Ft ¼ Ff  ðFf  FoÞeðkcat=KmÞ½Et ð1Þ
Ft ¼ Fo þ ðFf  FoÞðkcat=KmÞ½Et ð2Þ
where Ft is the ﬂuorescence intensity measured at a given time (t)
during the reaction, Fo is the intensity of the substrate prior to the
addition of enzyme, Ff is the intensity of the product when all the
substrates were cleaved with suﬃcient Mpro within a period of 30 min,
and [E] is the concentration of SARS-CoV Mpro used in the reaction.
Values of kcat=Km were determined either by non-linear least squares
regression analysis of all data using Eq. (1) or by linear least squares
regression analysis of initial velocity data using Eq. (2).
2.5. HTS for inhibitors of SARS-CoV Mpro
HTS was performed in quadruplicate in black polypropylene 96-well
plates (Greiner bio-one). Two microliters of the 104 compounds (1.0
mg/ml in dimethyl sulfoxide (DMSO)) was added to individual wells.
Fifty microlitersof 10 lM ﬂuorogenic peptide in Buﬀer A was then
delivered into each well with a QFill2 liquid dispenser (Genetix). The
reaction was initiated by addition of 50 ll of 200 nM SARS-CoV Mpro
in buﬀer A with the QFill2 liquid dispenser. Fluorescence intensity was
then measured with a Fusion Universal Plate Reader (Perkin–Elmer
Life Sciences) using an excitation wavelength of 335 nm and emission
wavelength of 535 nm. Fluorescence intensity change of each well was
calculated and then normalized to mean values when no compound
was added.
2.6. Ki of inhibitors of SARS-CoV Mpro
For determination of Ki of identiﬁed inhibitors, cleavage assays were
carried out at 25 C in buﬀer containing 20 mM Tris–HCl, pH 7.3, 150
mM NaCl, and 1% DMSO, with or without inhibitors. Two hundred
nanomolar of puriﬁed SARS-CoV Mpro was pre-incubated with the
buﬀer for 30 min and ﬂuorogenic substrate SP2 was added to a ﬁnal
concentration of 5 lM to initiate the reaction. Values of Ki were de-
termined by non-linear least squares regression analysis of data ﬁtted
to the following equation
ðkcat=KmÞi ¼ ðkcat=KmÞofKi=ðKi þ ½IÞg ð3Þ
where ðkcat=KmÞi and ðkcat=KmÞo are values in the presence and absence
of inhibitors, respectively, and [I] is the total concentration of inhibitor
added. At least six concentrations of inhibitors were used to obtain
ﬁnal Ki values.
2.7. Cell-based antiviral assays
SARS-CoV strain HKU 39849 was isolated from a SARS patient in
Hong Kong. The degree of protection oﬀered by the test compounds
against SARS-CoV infection was measured by Vero cell cytopathic
eﬀect (CPE) assay and plaque reduction assay (PRA). For CPE assay,
Vero cells were seeded at 2 104 cells per well (96-well microtitre plate)
in complete Eagle’s minimal essential medium (EMEM) (Invitrogen)
supplemented with 5% heat-inactivated fetal bovine serum (FBS) (In-
vitrogen), with or without the addition of test compounds. One hun-
dred TCID50 (50% tissue-culture infectious dose) of SARS-CoV was
added subsequently to each well. Assay plates were incubated at 37 C
in 5% CO2 and CPE of the infected cells were recorded 96 h post in-
fection using a Leica DMIL inverted microscope equipped with
DC300F digital imaging system (Leica Microsystems). For PRA, one
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individual wells of 24-well tissue culture plates (TPP) seeded with a
conﬂuent monolayer of Vero cells (1 105 cells per well) in EMEM
with 1% FBS. Plates were incubated at 37 C in 5% CO2 for 1 h. One
millilitre of overlay (1% low-melting agarose in EMEM with 1% FBS
and appropriate concentrations of inhibitors) was added to each well
after the media were aspirated. After 48 h of incubation at 37 C in 5%
CO2, cells were ﬁxed by adding 1 ml of 10% formaldehyde and the
agarose plugs removed. Cells were stained with 0.5% crystal violet in
70% methanol and the viral plaques counted. Experiments were carried
in quadruplicate and dose response data were best ﬁt to logistic
equation in SigmaPlot 8.0 (SPSS). The cytotoxicity of the inhibitors
was determined by MTT (3-[4,5-dimethylth-iazol-2-yl]-2,5-diphenyl-
tetrazolium bromide) assay (Roche) according to the manufacturer’s
instructions. All procedures involving manipulation of live SARS-CoV
were carried out in a biological safety level 3 containment laboratory.Fig. 2. (A) Initial ﬂuorescence intensity of ﬂuorogenic substrate SP2.
Results are expressed as ﬂuorescence intensity units (FIU). (B) Initial
cleavage rate of SP2 by SARS-CoVMpro. 0–800 nM of puriﬁed SARS-
CoV Mpro were used in the experiment.3. Results
3.1. Biosynthesis and puriﬁcation of recombinant SARS-CoV
Mpro
The His-tag recombinant SARS-CoV Mpro was successfully
expressed in E. coli and the full length authentic SARS-CoV
Mpro was puriﬁed to homogeneity after aﬃnity chromatogra-
phy, factor Xa cleavage, anion-exchange chromatography, and
size-exclusion chromatography. The described protocol yields
10 mg of puriﬁed protein from 4 liters of culture. The em-
ployment of a synthetic substrate SP1 mimicking the putative
autolytic cleavage site of the N-terminal part of Mpro in the
HPLC-based cleavage assay established the speciﬁcity of the
puriﬁed SARS-CoV Mpro (Fig. 1A). The turnover number of
SARS-CoV Mpro and Km on synthetic peptide SP1 was found
to be 0.54 0.04 s1 and 2.3 0.6 104 M, respectively, by
Lineweaver–Burk plot and the kcat=Km was calculated to be
2.4 0.6 103 M1 s1 (Fig. 1B).Fig. 1. (A) Speciﬁc cleavage of synthetic peptide SP1 by puriﬁed
SARS-CoVMpro. P1 and P2, cleavage products; S, uncleaved synthetic
substrate SP1. (B) Lineweaver–Burk plot for the determination of
SARS-CoV Mpro kinetic parameters in HPLC-based assays. The Km
and kcat of the SARS-CoV Mpro for substrate SP1 were determined by
incubation of SP1 at diﬀerent concentrations varying from 0.6 to 2.4
mM with 200 nM of SARS-CoV Mpro in 20 mM Tris–HCl, pH 7.3,
and 150 mM NaCl under conditions described in Section 2. The initial
rates of cleavage were determined under the condition that 5–10% of
the total substrate was cleaved. Experiments were carried out in trip-
licates and data points are expressed as meansS.D.3.2. Fluorescence-based kinetic analysis
The linearity of the initial ﬂuorescence intensity gradually
lost at concentrations above 10 lM of SP2 (Fig. 2A), a
property very similar to a ﬂuorogenic peptide designed for
cytomegalovirus (CMV) 3C-like protease [15]. When 5 lM of
SP2 was used, the initial rate of change of ﬂuorescence inten-
sity increased in a linear fashion with 100–800 nM of SARS-
CoV Mpro (Fig. 2B), indicating the usefulness of using this
ﬂuorescence-based substrate to conduct kinetic studies under
the speciﬁed conditions. Using 5 lM of SP2 and 100–600 nM
of SARS-CoV Mpro, a kcat=Km value of 2.9 0.2 104 M1 s1
was obtained by applying Eqs. (1) and (2).
3.3. HTS for inhibitors of SARS-CoV Mpro
The 104 compounds were screened at 20 lg/ml. The rate of
change of ﬂuorescence intensity was normalized to control in
the absence of inhibitors and the results are shown in Fig. 3.Fig. 3. HTS of small molecule inhibitors of SARS-CoV Mpro using
ﬂuorogenic substrate SP2. The initial cleavage rates of SARS-CoV
Mpro on ﬂuorogenic substrate SP2 in the presence of the test com-
pounds (104 compounds) were normalized to values in the absence
of compounds and expressed as arbitrary units (AU). Dotted line
indicates 0.5 AU.
Fig. 4. Chemical structures of SARS-CoV Mpro inhibitors and their chemical analogues. (A) Chemical structure of MP576 (3-quinolinecarboxylic
acid, 1,4,5,6,7,8-hexahydro-2-methyl-4-(2-nitrophenyl)-5-oxo-, 2-phenylethyl ester). (B) Chemical structure of MP521 (2-(2-nitrophenyl)-1,3-di-
phenyl-imidazolidine). (C) Chemical structure of CB5751. (D) Chemical structure of CB5173. CB5751 is an analogue of MP576 and CB5173 is an
analogue of MP521.
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rate of change of ﬂuorescence intensity when compared to the
control in the absence of inhibitors and were therefore selected
for further evaluations. Some of the hits were expected to be
false positives because of delivery errors, light scattering, or
optical absorbance of test compounds. The ﬁnal evaluation of
inhibitors was to be performed with a rigorous HPLC-based
cleavage assay that is not subject to these artifacts. Of the 10
compounds tested at a concentration of 20 lg/ml with 200 nM
SARS-CoV Mpro and 200 lM SP1 using the HPLC-based
assay, two exhibited >50% inhibitory eﬀects on the Mpro and
were therefore regarded as true inhibitors (data not shown).
The two identiﬁed inhibitors were designated MP576 and
MP521 and their chemical structures are shown in Fig. 4.
3.4. Ki of inhibitors of SARS-CoV Mpro
To determine the values of Ki, the concentration of the in-
hibitors was converted to molar units for more precise com-
parison of their inhibitory activities. The Ki values of MP576
and MP521 were calculated (applying Eq. (3)) to be 2.9 0.3
and 11 2 lM, respectively, using ﬂuorogenic substrate SP2
(Table 1).Table 1
Anti-SARS-CoV properties of MP576 and MP521
Compound Ki (lM) EC50 (lM) TC50 (lM)
MP576 2.9 0.3 7 2 >50
MP521 11 2 14 4 >503.5. Cell-based antiviral assays
At 10 lg/ml concentration, both inhibitors MP576 and
MP521 protected the monolayer of Vero cells from SARS-
CoV induced CPE (Fig. 5), indicating the promising antiviral
activities and the non-toxic properties of these two compounds
at the concentration tested. In addition, MP576 and MP521
inhibited the SARS-CoV plaque formation in Vero cells in a
concentration dependent manner with EC50 (median eﬀective
concentration) values of 7 2 and 14 4 lM, respectively
(Table 1), demonstrating that the protective eﬀects observed
were indeed due to the presence of Mpro inhibitors. Further-
more, the TC50 (median toxic concentration) values of MP576
and MP521 were determined to be >50 lM (Table 1), indi-
cating that these two compounds are not cytotoxic at their
eﬀective antiviral concentrations.4. Discussion
We set out to clone and to characterize the SARS-CoV Mpro
with the intention to develop an assaying system amendable
for HTS operations for isolating potential drug leads targeting
this ‘‘essential’’ component of the SARS-CoV. Since the ad-
ditional amino acid sequence present in recombinant Mpro
resulting from cloning procedures might have undesirable
properties in in vitro or in vivo assaying systems, we engi-
neered the recombinant SARS-CoV Mpro in a way that the
ﬁnal puriﬁed recombinant SARS-CoV Mpro will have amino
acid sequence identical to that of the authentic SARS-CoV
Mpro. After successive puriﬁcations employing aﬃnity chro-
matography, factor Xa cleavage, anion-exchange chromatog-
Fig. 5. Anti-SARS-CoV activities of MP576 and MP521. (A) Vero cells
infected with 100 TCID50 SARS-CoV. (B) Vero cells infected with 100
TCID50 SARS-CoV in the presence of 20 lg/ml of MP576. (C) Vero
cells infected with 100 TCID50 SARS-CoV in the presence of 20 lg/ml
of MP521. CPE were recorded 96 h post infection. Experiments were
carried out in duplicate and repeated twice.
Fig. 6. Inhibitory activity of analogues of MP576 and MP521 on
SARS-CoV Mpro. The cleavage of 10 lM of the ﬂuorogenic substrate
SP2 by 200 nM of puriﬁed SARS-CoV Mpro in 20 mM Tris-HCl, pH
7.3, and 150 mM NaCl at 25 C was monitored continuously by a
ﬂuorescence spectrophotometer in the presence or absence of 50 lM of
diﬀerent compounds. Background ﬂuorescence was subtracted for
clarity of comparison. Experiments were carried out in duplicate and
mean value of each data point was used for plotting.
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puriﬁed SARS-CoV Mpro with a kcat=Km value¼ 2.4 103
M1s1 using synthetic substrate SP1 and a kcat=Km
value¼ 2.9 104 M1 s1 using ﬂuorogenic substrate SP2. The
kinetic parameters obtained were comparable to that of other
viral 3C-like proteases reported [16,17]. We noticed that the
kcat=Km value (calculated to be 1.8 102 M1 s1) published by
Lai’s group on a synthetic peptide substrate (H2N-
TSAVLQSGFRK-COOH) [18,19] is about 10-fold lower than
the one we obtained with our synthetic peptide substrate SP1
(H2N-TSAVLQSGFRKW-COOH; kcat=Km value¼ 2.4 103
M1 s1). Aside from diﬀerences in puriﬁcation procedures
and assaying conditions, and slight diﬀerence in amino acid
sequence between the two peptides, we do not have an expla-
nation for the apparent discrepancy between the results ob-
tained by the two groups.
The ﬂuorogenic substrate SP2 used in the study is very
sensitive for assaying the cleavage activity of the SARS-CoV
Mpro. As little as 6.5 nM of the SARS-CoV Mpro could be
detected in the assaying system we employed (data not shown).
This ultra-sensitive substrate, however, could not be used at
concentrations higher than 10 lM due to its internal quench-
ing eﬀects [15]; this property rendered SP2 unsuitable for the
determination of Km of the assay system. Nevertheless, SP2 has
been demonstrated to be an excellent substrate for HTS pur-
poses and for evaluation of inhibitor potencies.
The two small molecule compounds identiﬁed in our study
are novel non-peptide inhibitors of SARS-CoV Mpro. The fact
that they inhibited the SARS-CoV Mpro with Ki values around
10 lM protected Vero cells from viral infection at comparable
concentrations and exhibited low cytotoxicity towards Vero
cells makes them promising leads for anti-SARS drug devel-
opment. Further investigations using analogues (CB5751 and
CB5173) of these two SARS-CoV Mpro inhibitors suggested
that the position of the nitro group in both inhibitors con-
tributes substantially to their inhibitory activities; changing the
2-nitro group to 3-nitro group (Fig. 4C, D) readily reduced the
compounds’ ability to inhibit the SARS-CoVMpro (Fig. 6). We
speculate that the 2-nitro group may be involved in forming
productive bonding in the inhibitor-enzyme complex. Further
structure-activity relationship studies employing more ana-
logues of the identiﬁed compounds and site-directed muta-
genesis with the SARS-CoV Mpro will help us to elucidate the
mode of actions of these two novel inhibitors. While this
manuscript is in preparation, a number of groups reported the
cloning and production of diﬀerent versions of the SARS-CoV
Mpro [20,21]. Others described the development of in vitroassays for screening SARS-CoV Mpro inhibitors [22,23]. We
report here the detailed kinetic analysis of a recombinant
SARS-CoV Mpro with amino acid sequence identical to that of
the authentic SARS-CoV Mpro and the successful identiﬁca-
tion of potent small molecule inhibitors of the Mpro with
demonstrated anti-SARS-CoV activities in cellular models.
With the establishment of assaying systems to examine the
in vitro cleavage and the cellular anti-SARS-CoV activities, we
can now start lead optimization by using focused combinato-
rial chemical libraries to understand the structure-activities
relationship of the two leads and to yield compounds with far
superior antiviral activities.
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